Skip to main content
investors

Investor Relations


Welcome to our dedicated page for investor resources. You will find everything you need if you want to invest in pioneering medical science.

Dedicated to solving some of today’s biggest public health challenges, bioMérieux has the focus and the capabilities to discover, develop, and commercialize advanced medical diagnostics solutions that have an impact on people’s lives. We combine the dynamism of a technology-fueled company with the long-term thinking of our founding family. It is this alliance that shapes our strategy and success.

A values-based company, we aim for strong and sustainable performance that benefits our shareholders, our employees, and society.

Investors

Third-Quarter 2023 Business Review

  • +8.0% sales organic growth over the first nine months of the year
    • €2,668 million in sales
    • +4.2% as reported 
  • Q3 sales organic growth at +7.1% (+10.3% excluding BIOFIRE® respiratory panels), on par with expectations
  • BIOFIRE® non-respiratory panels grew by +24% in Q3 thanks to successful cross-selling by leveraging the large BIOFIRE® installed base and the broadest menu in the market 
  • Remarkable resilience of the BIOFIRE® respiratory panels sales (-2% over the 9 months period, -5% in Q3) in a 2023 post COVID environment, demonstrating the value of the syndromic solution
  • Strong momentum in clinical microbiology (+11% in Q3) thanks to the continued uptake of the VITEK® MS PRIME and the relevance of the product portfolio to support the fight against Antimicrobial Resistance
  • Promising launch of BIOFIRE® SPOTFIRE® with close to 400 installed instruments at the end of September 2023 and high customers interest. On-going geographical expansion out of the US with the start in Japan, and broadening of the menu through the FDA filing of the BIOFIRE® SPOTFIRE® Respiratory Sore Throat panel in October
  • Confirmation of the 2023 guidance:
    • Organic sales growth between +4 and +6%
    • Contributive operating income before non-recurring items should be in a range of €600 million to €630 million 

“bioMérieux delivered a solid performance during the third quarter of 2023. The BIOFIRE® non-respiratory panels kept on growing at a very strong pace while respiratory panels sales were resilient. In addition, the microbiology franchise performed very well, driven by both volumes and prices increases. We expect BIOFIRE® respiratory panels sales to be lower in Q4 2023 than in Q4 2022, inflated by the triple-demic, but we are confident to achieve our full year targets.”

Pierre Boulud, CEO

Working at home with laptop woman writing a blog. Female hands on the keyboard.

URD/Annual Reports

See most comprehensive information about bioMérieux.

CSR

Discover our plans to a sustainable future.

Governance

Our boards and committees underpin our ability to make decisions and ensure control processes. 

Working at home with laptop woman writing a blog. Female hands on the keyboard.

News & publications

bioMérieux combines long-term growth and profitability. Learn more about our performance and activities in our detailed reports and financials.

Analysts coverage & consensus

Financial analysts keep track of our performance. Discover their forecasts here.

Shareholder Area

Already a bioMérieux shareholder or want to start investing?

Close up Business people meeting to discuss the situation on the market. Business Financial Concept

Regulated Information

To guarantee transparency and sustainability, we abide by a strict set of rules and regulations.